Table 4 Reasons for discontinuation of first and second JAK inhibitors

#1 (63/F)

Tofacitinib

Primary failure

Baricitinib

Secondary failure

#2 (62/F)

Tofacitinib

Primary failure

Baricitinib

Secondary failure

#3 (48/F)

Tofacitinib

Primary failure

Baricitinib

Adverse event

#4 (45/F)

Tofacitinib

Primary failure

Upadacitinib

N/A^a

#5 (40/F)

Tofacitinib

Secondary failure

Baricitinib

Primary failure

#6 (61/F)

Tofacitinib

Secondary failure

Baricitinib

Primary failure

#7 (58/F)

Tofacitinib

Primary failure

Baricitinib

Primary failure

#8 (66/M)

Tofacitinib

Secondary failure

Baricitinib

Secondary failure

#9 (49/F)

Tofacitinib

Primary failure

Baricitinib

Primary failure

#10 (56/F)

Tofacitinib

Primary failure

Baricitinib

Primary failure

#11 (59/F)

Tofacitinib

Primary failure

Baricitinib

Primary failure

#12 (60/M)

Tofacitinib

Primary failure

Baricitinib

Secondary failure

#13 (68/F)

Tofacitinib

Secondary failure

Baricitinib

Adverse event

#14 (55/F)

Tofacitinib

Secondary failure

Baricitinib

Insurance coverage issue

#15 (35/F)

Tofacitinib

Primary failure

Baricitinib

Insurance coverage issue

#16 (50/F)

Tofacitinib

Primary failure

Baricitinib

N/A^a

#17 (49/F)

Tofacitinib

Primary failure

Baricitinib

N/A^a

#18 (49/F)

Tofacitinib

Primary failure

Baricitinib

N/A^a

#19 (58/F)

Tofacitinib

Primary failure

Baricitinib

N/A^a

#20 (35/F)

Tofacitinib

Secondary failure

Baricitinib

N/A^a

#21 (58/F)

Tofacitinib

Primary failure

Baricitinib

N/A^a

#22 (65/F)

Tofacitinib

Primary failure

Baricitinib

N/A^a

#23 (40/F)

Tofacitinib

Adverse event

Baricitinib

Primary failure

#24 (57/F)

Tofacitinib

Adverse event

Baricitinib

Secondary failure

#25 (56/F)

Tofacitinib

Adverse event

Baricitinib

Primary failure

#26 (35/F)

Tofacitinib

Adverse event

Baricitinib

Primary failure

#27 (68/F)

Tofacitinib

Adverse event

Baricitinib

Insurance coverage issue

#28 (34/F)

Baricitinib

Adverse event

Tofacitinib

Insurance coverage issue

#29 (54/F)

Tofacitinib

Adverse event

Baricitinib

N/A^a

#30 (57/F)

Tofacitinib

Adverse event

Baricitinib

N/A^a

#31 (62/F)

Tofacitinib

Adverse event

Baricitinib

N/A^a

#32 (61/F)

Baricitinib

Adverse event

Tofacitinib

N/A^a